Do you want to read an article? Please log in or register.
Efficacy and safety of rituximab in comparison with common induction therapies in pediatric active lupus nephritis
Systemic Lupus Erythematosus
Related content
Psoriatic Arthritis
Comparative efficacy and safety of targeted DMARDs for active psoriatic arthritis during induction therapy: A systematic review and network meta-analysis
Semin Arthritis Rheum.
Lu C, Wallace BI, Waljee AK, Fu W, Zhang Q, Liu Y
doi: 10.1016/j.semarthrit.
Autoimmune Disease
Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study
Lancet.
van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S
doi: 10.1016/S0140-
Systemic Lupus Erythematosus
Efficacy and safety of anti-CD20 antibody rituximab for patients with refractory systemic lupus erythematosus
Lupus.
Iwata S, Saito K, Hirata S, Ohkubo N, Nakayamada S, Nakano K, Hanami K, Kubo S, Miyagawa I, Yoshikawa M, Miyazaki Y, Yoshinari H, Tanaka Y
doi: 10.1177/0961203317749047.
Systemic Lupus Erythematosus
The short-term efficacy of bortezomib combined with glucocorticoids for the treatment of refractory lupus nephritis
Lupus.
Zhang H, Liu Z, Huang L, Hou J, Zhou M, Huang X, Hu W, Liu Z
doi: 10.1177/0961203316686703.
Further Publications Dermatology
Efficacy and safety of voclosporin versus placebo for lupus nephritis (AURORA 1): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial
Lancet
Rovin BH, Teng YKO, Ginzler EM, Arriens C, Caster DJ, Romero-Diaz J, Gibson K, Kaplan J, Lisk L, Navarra S, Parikh SV, Randhawa S, Solomons N, Huizinga RB
doi: 10.1016/S0140-6736(21)00578-X
COMMENTED
Psoriatic Arthritis
A head-to-head comparison of the efficacy and safety of ixekizumab and adalimumab in biological-naïve patients with active psoriatic arthritis: 24-week results of a randomised, open-label, blinded-assessor trial
★ 3
Recommended and commented by
Dr Heino Prillwitz, Faculty Member
Ann Rheum Dis.
Mease PJ, Smolen JS, Behrens F, Nash P, Liu Leage S, Li L, Tahir H, Gooderham M, Krishnan E, Liu-Seifert H, Emery P, Pillai SG, Helliwell PS, SPIRIT H2H study group.
doi: 10.1136/annrheumdis-2019-215386.
Systemic Lupus Erythematosus
Two-Year, Randomized, Controlled Trial of Belimumab in Lupus Nephritis
N Engl J Med.
Furie R, Rovin BH, Houssiau F, Malvar A, Teng YKO, Contreras G, Amoura Z, Yu X, Mok CC, Santiago MB, Saxena A, Green Y, Ji B, Kleoudis C, Burriss SW, Barnett C, Roth DA
doi: 10.1056/NEJMoa2001180.
Rheumatoid Arthritis
Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study
Lancet.
Aletaha D, Bingham CO 3rd, Tanaka Y, Agarwal P, Kurrasch R, Tak PP, Popik S
doi: 10.1016/
Rheumatoid Arthritis
Efficacy and safety of Sandoz biosimilar rituximab for active rheumatoid arthritis: 52-week results from the randomized controlled ASSIST-RA trial
Rheumatology (Oxford).
Smolen JS, Cohen SB, Tony HP, Scheinberg M, Kivitz A, Balanescu A, Gomez-Reino J, Cen L, Poetzl J, Shisha T, Kollins D
doi: 10.1093/rheumatology/keaa234.